202-CoV
This is an old revision of this page, as edited by Liaton9000 (talk | contribs) at 16:53, 21 October 2022. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Protein subunit |
Clinical data | |
Routes of administration | Intramuscular |
Part of a series on the |
COVID-19 pandemic |
---|
![]() |
|
Medical response |
|
![]() |
202-CoV is a COVID-19 vaccine candidate developed by Shanghai Zerun Biotechnology Co., Ltd., Walvax Biotech.[1][2][3] It is one of several candidates under development by Walvax.
Development
In May 2020, the Bill & Melinda Gates Foundation awarded Shanghai Zerun Biotechnology a $1,000,000 USD vaccine development grant to "support research and development for COVID-19 response".[4]
In July 2021, the Coalition for Epidemic Preparedness Innovations (CEPI) announced that it had partnered with Shanghai Zerun Biotechnology and its parent company, Walvax Biotech, to develop COVID-19 vaccine candidates against both the original strain of SARS-CoV-2 and its newer variants.[3] As of October 2022, CEPI had provided up to $25.1 million USD towards 202-CoV, but had ceased further funding.[5] The chimeric protein candidate remains in Phase I clinical trials.
References
- ^ Clinical trial number NCT04982068 for "Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell)" at ClinicalTrials.gov
- ^ Clinical trial number NCT04990544 for "Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell)" at ClinicalTrials.gov
- ^ a b "CEPI partners with Shanghai Zerun Biotech to develop COVID-19 variant vaccine". Coalition for Epidemic Preparedness Innovations. 21 July 2021. Retrieved 30 August 2021.
- ^ "Shanghai Zerun Biotechnology Co., Ltd". Bill & Melinda Gates Foundation. May 2020. Archived from the original on 21 October 2022. Retrieved 21 October 2022.
- ^ "Our portfolio". Coalition for Epidemic Preparedness Innovations (CEPI). Archived from the original on 21 October 2022. Retrieved 21 October 2022.
![](http://upload.wikimedia.org/wikipedia/commons/thumb/3/32/Scholia_logo.svg/40px-Scholia_logo.svg.png)
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
![]() | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
![]() | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
- Articles with short description
- Short description matches Wikidata
- Use dmy dates from August 2021
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a vaccine
- All stub articles